Shots:

• The agreement involves assessing safety- efficacy and tolerability of BeiGene's RAFi dimer- lifirafenib (BGB-283) and SpringWorks' MEKi (PD-0325901)- in patients with advanced solid tumours
•  BeiGene will look forward for onset of P-Ib trial for advanced solid tumours while SpringWorks will oversee fixed dosing formulation in trial
• The P-Ib trial is expected to initiate in Q1’19 while the costing and governance responsibilities of the trial will be shared equally b/w both the companies

Ref: BeiGene | Image:  Capital Watch